Raising 'good' cholesterol fails to protect against heart disease

November 16, 2017, University of Oxford
Raising 'good' cholesterol fails to protect against heart disease. Credit: Shutterstock

Raising so-called 'good' cholesterol by blocking a key protein involved in its metabolism does not protect against heart disease or stroke, according to a large genetic study of 150,000 Chinese adults published in the journal JAMA Cardiology.

There are two types of cholesterol in the blood: LDL-C, so-called 'bad' cholesterol, which is carried in low-density lipoproteins (LDL), and HDL-C, so-called 'good' cholesterol which is found in high-density lipoproteins (HDL).

Lowering LDL-C (e.g. by statins) has been demonstrated to reduce the risk of heart diseases and stroke, but the causal role of HDL-C is less clear even though observational studies have shown an inverse association between HDL-C and risk of cardiovascular diseases.

Cholesterol ester transfer protein (CETP) transfers cholesterol between different lipoproteins. Blocking this protein, which raises levels of HDL-C as well as causing other changes to blood lipids, is a potentially important approach for prevention and treatment of cardiovascular diseases. Genetic variants which alter the activity of CETP can mimic some of the effects of drugs which target this protein and can be used to help assess the potential benefits and harms of this cholesterol-modifying treatment.

Researchers at the University of Oxford, Peking University and Chinese Academy of Medical Sciences explored the health effects of CETP genetic variants, including an East Asian specific functional variant, in 150,000 Chinese adults enrolled into the China Kadoorie Biobank (CKB). After ten years of follow-up, over 5,000 study participants had and 19,000 had a stroke.

The researchers found that CETP genetic variants raised levels of HDL-C substantially, but did not lower LDL-C and did not lower the risk of cardiovascular diseases such as heart disease and stroke. There was also no effect on atherosclerotic plaques and thickness of the arteries, or on other conditions such as diabetes and kidney disease. However, the study found increased risk of eye diseases as a possible adverse effect of CETP inhibition, a finding which is supported by other genetic studies in East Asian and Western populations.

In this study of genetic variants which alter CETP activity, raising HDL-C without also lowering LDL-C did not result in a benefit for heart disease or stroke. The study results complement findings from the recent REVEAL clinical trial of the CETP inhibitor anacetrapib, which found that beneficial effects of CETP inhibition for were more likely to be due to lowering 'bad' cholesterol LDL-C than raising 'good' HDL-C.2.

New treatments are discovered by exploring biological pathways that cause disease but can be modified by drugs. The journey from basic biology to large-scale randomised trials in humans is long and expensive: the estimated cost of getting a single product to market is over $2 billion. Using genetic data to predict the benefits and harms of new treatments can reduce costs and improve the drug development pipeline.

This approach is likely to become much more widely used to examine the causal nature of biological pathways involved in diseases before mounting large-scale clinical trials in the future. Many thousands of functional genetic variants are known which may represent potential drug targets in different biological pathways, and the research teams are using the same approach to assess a number of other important therapeutic targets.

Study author Dr Iona Millwood, from the University of Oxford, said: "Our research has helped clarify the role of different types of , and suggests that raising levels of HDL-C by blocking CETP activity, without also lowering LDL-C, does not confer any major benefits for cardiovascular disease."

Professor Liming Li, study co-author from Peking University, said: "CKB is a powerful resource for collaborative research that can inform not only the relevance of lifestyle factors (e.g. smoking, diet and physical activity) for health but also drug development."

Professor Zhengming Chen, study co-author at the University of Oxford, added: "This study demonstrates the value of large prospective biobank studies with genetic data linked to health records, carried out in diverse global populations, to predict the potential benefits or harms of new drug treatments."

The full paper, "Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults," is published in the journal JAMA Cardiology.

Explore further: Anacetrapib reduces risk of serious cardiovascular events in high risk patients on statins

More information: Iona Y. Millwood et al. Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults, JAMA Cardiology (2017). DOI: 10.1001/jamacardio.2017.4177

Related Stories

Anacetrapib reduces risk of serious cardiovascular events in high risk patients on statins

August 29, 2017
Anacetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) activity, lowers the risk of heart attack and related cardiovascular complications in patients receiving intensive statin treatment, according to late-breaking ...

New genetic research can significantly improve drug development

June 15, 2016
According to a new study published in the International Journal of Epidemiology this week, genetic research in large-scale prospective biobank studies can significantly improve the drug development pipeline and reduce costs.

Evacetrapib impacts cholesterol but doesn't reduce cardiovascular events

April 3, 2016
Cleveland Clinic researchers studying evacetrapib have shown that despite reducing levels of low-density lipoprotein (LDL, or "bad" cholesterol) by 37 percent and raising levels of high-density lipoprotein (HDL, or "good" ...

Experimental drug raises 'good' cholesterol, may help control diabetes

July 18, 2011
A medicine designed to improve levels of "good" cholesterol may also help control blood sugar in people with diabetes who are taking cholesterol-lowering drugs, according to a new analysis in Circulation: Journal of the American ...

Recommended for you

Heart failure patients shouldn't stop meds even if condition improves: study

November 13, 2018
(HealthDay)—There's bad news for heart failure patients with dilated cardiomyopathy who'd like to stop taking their meds.

Bypass beats stents for diabetics with heart trouble: study

November 13, 2018
(HealthDay)—People with both diabetes and multiple clogged heart arteries live longer if they undergo bypass surgery rather than have their blood vessels reopened with stents, according to follow-up results from a landmark ...

Kawasaki disease: One disease, multiple triggers

November 12, 2018
Researchers at University of California San Diego School of Medicine, Scripps Institution of Oceanography, and international collaborators have evidence that Kawasaki Disease (KD) does not have a single cause. By studying ...

New treatment significantly reduces cardiovascular events when combined with statins

November 12, 2018
Statins are the most commonly used treatment for cardiovascular disease. Despite reducing certain risk factors, if triglyceride levels remain high with use of statins, there is still a significant risk for heart attack, stroke ...

Study: How vitamin D and fish oil affect risk of heart attack, stroke and cancer

November 12, 2018
For years, it's remained an open question: What effects do dietary supplements such as high doses of vitamin D or omega-3 fatty acids derived from fish oil have on the risk of diseases such as heart attack, stroke and cancer? ...

Diabetes drug might also ease heart failure risks

November 12, 2018
(HealthDay)—The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows.

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

MR166
not rated yet Nov 16, 2017
The most important factor is lowering triglycerides via a low glycemic index diet. That means not eating milled grain products, white potatoes, sugar and rice. Do that and all of the lipids, blood sugar numbers and weight will fall into place naturally. Food cravings will disappear. If it has a glycemic index above 50 do not eat it.
MR166
not rated yet Nov 16, 2017
Poor lipid and triglyceride levels are just an indicator of poor diet. Hiding the indicators does not cure the problem.
MR166
not rated yet Nov 16, 2017
Also inflammation, wherever it occurs in the body including the gums is a huge factor in artery disease. The statin pushers never mention this.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.